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The Caprine arthritis encephalitis virus (CAEV) vif gene was demonstrated to be essential for efficient virus replication.
CAEV Vif deletion mutants demonstrated an attenuated replication phenotype in primary goat cell cultures and resulted in
abortive infection when inoculated into goats. In this study, we determined the in vitro replication phenotype of five CAEV Vif
point mutant infectious molecular clones and the ability of the corresponding in vitro translated Vif proteins to interact with
the CAEV Pr55gag in the glutathione S–transferase (GST) binding assay. Here we show that (i) three of the mutants (S170E,
S170G, S197G) behaved as the wild-type CAEV according to virus replication and Vif–Gag interactions; (ii) one mutant (Vif
6mut) was replication incompetent and bound weakly to GST–Gag fusion proteins; and (iii) one mutant (Vif RG) was impaired
for replication while retaining its interaction properties. This mutant points out the critical importance of the CAEV Vif
tryptophan residue at position 95 for efficient virus replication, defining for this lentivirus a functional domain unrelated to the
Gag binding region. © 2001 Academic Press
Key Words: lentivirus; CAEV; replication; Vif mutants; interaction; functional domain.
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kINTRODUCTION
Caprine arthritis encephalitis virus (CAEV) is a lentivi-
rus that infects goats worldwide and induces progres-
sive degenerative inflammatory diseases in infected an-
imals. The CAEV genome is related to other lentiviruses,
and it harbors a vif gene in addition to the structural (gag,
pol, env) and regulatory (tat, rev) genes (Saltarelli et al.,
1990). The vif gene is present in the genome of all known
entiviruses, except the equine infectious anemia virus
EIAV) (Oberste and Gonda, 1992), and is required in vivo
o establish persistent infection and pathogenesis of
AEV, simian immunodeficiency virus (SIV) and feline
mmunodeficiency virus (FIV) (Desrosiers et al., 1998;
armache et al., 1996; Inoshima et al., 1996). Our previ-
us results clearly show that in vitro infection of primary
oat synovial membrane cells or blood-derived macro-
hages with different CAEV Vif deletion mutants resulted
n strongly attenuated virus replication due to a defect in
he late stage of virus production (Harmache et al., 1995).
n vitro studies on vif genes mutants of HIV-1, FIV, and SIV
evealed that the phenotype is dependent on the host
ell type from which the virus is produced (Courcoul et
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232l., 1995; Fan and Peden, 1992; Fisher et al., 1987;
abuzda et al., 1992; Gibbs et al., 1994; Lockridge et al.,
999; Sakai et al., 1993; Shacklett and Luciw, 1994; Sova
nd Volsky, 1993; Tomonaga et al., 1992; von Schwedler
t al., 1993). These results suggested crucial interac-
ion(s) between Vif and host cell factor(s) for production
f infectious virus. Altogether these findings are consis-
ent with the idea that Vif functions at a late stage of the
iral cycle such as assembly, budding, release, or mat-
ration. However studies on HIV-1 Vif2 virions reported
contradictory results in core protein composition
(Bouyac et al., 1997b; Fouchier et al., 1996; Ochsenbauer
t al., 1997; Simm et al., 1995) and core morphology
Borman et al., 1995; Hoglund et al., 1994). In the same
ay, analyses of HIV-1-infected cells produced conflict-
ng data in regard to the co-localization of Vif and Gag
nd their association to cellular membranes (Goncalves
t al., 1995; Michaels et al., 1993; Simon et al., 1999a,
1997), while others demonstrated HIV-1 Vif and Pr55gag
interactions (Bouyac et al., 1997a; Huvent et al., 1998).
rom all these studies, it comes out that a comprehen-
ive knowledge of the Vif function(s) is still lacking.
Understanding the function of a protein at the molec-
lar level needs the determination of functional motifs or
omains. Although the different Vif proteins share little
equence homology, they all are highly basic proteins
ith an unusually high content in tryptophan residues. A
onserved motif, SLQXLA, was identified among all the
nown Vif sequences (Oberste and Gonda, 1992) and
emonstrated to be important for function (Harmache et
l., 1995; Simon et al., 1999b; Yang et al., 1996). Another
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233FUNCTIONAL DOMAIN OF CAEV VIF PROTEINcommon characteristic is the presence of potentially
phosphorylated serine threonine residues. In the case of
HIV-1, the phosphorylation of Ser144, contained within the
onserved SLQXLA motif, was demonstrated to be im-
ortant for virus replication (Yang et al., 1996). The CAEV
if protein also contains several serine/threonine resi-
ues that could potentially be phosphorylated, especially
er170, within the SLQXLA motif, and Ser197. Both of them
re in the context of recognition motifs (R/KXXS*/T*) used
y serine/threonine protein kinase such as cAMP- and
GMP-dependent protein kinase.
Defining functional domains of the CAEV Vif protein
ould help to understand the molecular mechanisms
hat underlie the function of this essential gene in CAEV
eplication and pathogenesis. In this study, we deter-
ined the replication phenotype of five CAEV Vif point
utants, and we analyzed the ability of the correspond-
ng Vif proteins to interact with the CAEV Pr55gag in the in
itro glutathione S–transferase (GST) binding assay. Be-
ides the fact that this work demonstrates that the Vif/
ag interaction seems to be conserved among distantly
elated lentiviruses such as CAEV and HIV-1, it identifies
functional domain of CAEV Vif, essential for virus rep-
ication, but distinct from the Gag binding region.
RESULTS
utational analysis of the CAEV Vif protein
To define amino acid residues important for Vif func-
ion, several Vif point mutants were created by PCR (Fig.
). We focused on the potentially phosphorylated Ser
esidues at positions 170 and 197 since many protein–
rotein interactions are governed by phosphorylation.
oreover, Ser170 belongs to the Vif-conserved SLQXLA
otif. Serine was replaced by a glycin (mutants S170G
FIG. 1. Schematic representation of the five Vif mutant proteins used
in this study. The vif gene mutants were obtained by PCR as described
nder Materials and Methods; they were either used for in vitro protein
ranslation for the GST binding assay or subcloned into the CAEV
olecular clone for replication phenotype determination.nd S197G) or by a glutamic residue (mutant S170E) to
imic phosphorylation by replacing the potential phos-ho-Ser by a negatively charged amino acid residue in
his latter case (Alessi et al., 1994; Zhao et al., 1994).
uring the selection of these mutants, two additional
utants were randomly obtained: the Vif RG mutant con-
aining a W95R substitution in addition to S197G and the
if 6mut where the 120–124 DRHFW sequence was re-
laced by SIVSR in addition to the S170G substitution.
nterestingly, Trp at position 95 as well as Phe-Trp at
osition 123–124 are strictly conserved among the differ-
nt sequenced maedi-visna and CAEV isolates (Que´rat
t al., 1990; Saltarelli et al., 1990; Sargan et al., 1991;
onigo et al., 1985). Each of the vif mutants described
bove was then subcloned into the PK-9kb plasmid,
ontaining most of the CAEV proviral DNA (Turelli et al.,
996), using the overall strategy described under Mate-
ials and Methods. Viral supernatants were obtained by
o-transfection of CFSM cells with each of PK-9kb plas-
id, containing wt or mutant vif genes, with the overlap-
ing BS-39LTR plasmid (Turelli et al., 1996), coding for the
emaining sequence of CAEV proviral DNA. Viral replica-
ion was monitored by measuring the reverse transcrip-
ase (RT) activity contained within cell-free supernatants
ollected after transfection. Infection experiments were
erformed with equal amounts of RT activity, and repre-
entative replication curves of the different CAEV Vif wt
r mutants are shown in Fig. 2. As can be seen in Fig. 2A,
he introduction of new BamHI and MluI sites in the vif
ene (Vif wt B/M) had no effect on the virus phenotype
ince both CAEV Vif wt or Vif wt B/M had similar repli-
ation profiles, with a peak in virus production at 12–16
ays p.i. In the same way, infection of CFSM cells with
AEV Vif S170E or Vif S170G resulted in a Vif phenotype
omparable to the CAEV Vif wt B/M (Fig. 2A). Sequencing
f late recovered viruses demonstrates no reversion of
hese mutants to the Vif wt sequence (data not shown).
n the contrary, when infection was performed with
AEV Vif 6mut, only background level of RT activity could
e detected (Fig. 2A), characteristic of the Vif2 pheno-
ype. These results indicated that the serine residue at
osition 170 was not involved in the Vif replication phe-
otype. However, changing the amino acid sequence at
ositions 120–124 had serious consequences on virus
eplication.
When compared to CAEV Vif wt B/M, CAEV Vif S197G
nduced a similar productive infection in CFSM cells (Fig.
B). This result demonstrated the irrelevant role of
er197 in virus replication as also shown above for
er170. The wt replication phenotype of CAEV Vif S197G
ould not be due to a reversion to the Vif wt since no
odification was observed in the virus sequences ob-
ained at late time points (data not shown). In contrast,
nfection with CAEV Vif RG resulted in a strongly atten-
ated Vif2 phenotype (CAEV Vif RG-1, Fig. 2B). CAEV Vif
RG-1 cell-free supernatants were taken at various time
p.i., and the RT–PCR products of the viral RNA were
submitted to nucleotide sequencing. The deduced amino
m
termine
activity
234 SEROUDE ET AL.acid sequences, between positions 26–216, are summa-
rized in Fig. 3. When compared to the Vif wt primary
sequence, the original Vif RG sequence deduced from
the CAEV molecular clone harbored the two amino acid
substitutions introduced by PCR, i.e., W95R and S197G.
Among the five amino acid sequences shown, deduced
from CAEV Vif RG-1 virions obtained after three different
infection experiments, one had a stop codon at position
49 (Vif RG-1a), resulting in a truncated Vif protein. The
four other clones (Vif RG-1b, -1c, -1d, and -1e) had full-
length Vif sequences still containing the original W95R
FIG. 2. Replication phenotype of the different CAEV Vif mutants. Viral
embrane cells (CFSM) with the PK-9kb plasmids containing the diffe
proviral DNA. The replication phenotype of the resulting viruses was de
viral stock. The virus production was monitored by measuring the RTand S197G mutations. Three of them also harbored one
or two additional amino acid changes introduced at dif-ferent non-conserved positions of the known maedi-
visna/CAEV Vif sequences, except the G53R substitution
in the Vif RG-1d sequence. Since all these replication
attenuated clones harbored the original W95R S197G
mutations, it could be assumed that the additional ran-
dom mutations detected are unrelated to the modifica-
tion of the virus phenotype. Surprisingly, in some other
infection experiments, using different viral stocks, CAEV
Vif RG was able to establish a productive infection show-
ing a Vif wt phenotype (CAEV Vif RG-2, Fig. 2B). Analysis
of the Vif protein sequences deduced from three CAEV
upernatants were obtained by co-transfection of primary goat synovial
f mutants and the BS-39LTR clone to allow reconstitution of complete
d by infection of CFSM cells with equal amounts of RT activity of each
present in the cell-free supernatant.stock s
rent viVif RG-2 clones revealed that the arginine residue intro-
duced at position 95 was reverted to a tryptophan, like in
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235FUNCTIONAL DOMAIN OF CAEV VIF PROTEINthe Vif wt clone, while the original S197G mutation re-
mained. As for the Vif RG-1 clones, some additional
mutations were detected at non-conserved positions in
two of three clones. From these results, it appeared that
reversion from Arg to Trp at position 95 was clearly
associated to restoration of the Vif wt phenotype in the
corresponding virus population (Fig. 2B). Since Vif/Gag
interaction was described to be related to the biological
activity of HIV-1 Vif, it appeared interesting to test
whether this might also be the case for the CAEV Vif
protein, and whether this interaction would take place
with the replication defective CAEV Vif mutants.
CAEV Vif protein interacts in vitro with the NC
omain of the Pr55gag
The CAEV vif gene was cloned in frame with the GST
ene to produce the GST–Vif fusion protein. After binding
o glutathione beads, GST or GST–Vif proteins were al-
owed to react with in vitro translated 35S-methionine-
labelled CAEV Pr55gag. As shown in Fig. 4A, radiolabelled
Gag protein was revealed by autoradiography after bind-
ing to GST–Vif, but not to GST, in the presence of 0.15 M
NaCl. Conversely, the GST–Gag fusion protein showed a
strong interaction with 35S-labelled Vif protein, even in
the presence of 0.5 M NaCl (Fig. 4B). No binding was
observed between GST–Gag and in vitro translated 35S-
labelled luciferase (data not shown), suggesting the
specificity of the interaction. These results demonstrated
an in vitro interaction between CAEV Vif and Gag pro-
teins. However, the difference in maximal ionic strength
allowing binding between GST-Vif/Gag and GST-Gag/Vif
might reflect a particular conformation of the GST–Vif
fusion protein resulting in minimal fixation of Gag.
In the next step, we characterized which domain of the
Pr55gag was involved in this interaction using GST fusion
FIG. 3. Alignment of the Vif amino acid sequences. The vif gene
ltra-centrifugation of cell-free supernatants. The Vif amino acid seq
equences and are shown in comparison to the Vif wt sequence. Gap
01 and 215 since no modifications were observed in these regions co
n bold are those which were found mutated in the different Vif isolate
ntroduced. *, stop codon.roteins expressing the different mature domains of Gag.
n vitro translated 35S-labelled Vif protein was tested for
d
minding with equal amounts of GST–CA, GST–MA, or
ST–NC, in the presence of NaCl concentration ranging
rom 0.1 to 0.5 M. As shown in Fig. 4B, the CAEV Vif
rotein was unable to interact with GST–CA and bound
eakly to GST–MA at 0.1 M NaCl. On the contrary, inter-
ction with GST–NC was as efficient as with GST–Gag.
he CAEV NC harbors two zinc (Zn) finger motifs of the
X2CX4HX4C type (Saltarelli et al., 1990). To determine if
he Zn finger motifs were involved in the GST–NC/Vif
nteraction, mutations were introduced to disturb the
verall folding of one or the other of these motifs. The
mino acid sequence of the first Zn finger motif (Z1) in
he CAEV NC is located at positions 20–33 and the
econd one (Z2) at positions 39–52. PCR mutagenesis
as used to replace cystein by glycin residues at posi-
ions 20 and 23 in Z1 and 39 and 42 in Z2. The corre-
ponding NC mutant genes were cloned in frame with
he GST gene to produce the GST–NC Z1* and GST–NC
2* fusion proteins. These proteins were compared to
he wild-type (wt) GST–NC for their ability to bind in vitro
ranslated 35S-labelled Vif protein (Fig. 4C). Mutations in
either the Z1 or Z2 motifs of the CAEV NC resulted in 8-
to 10-fold less interaction with Vif compared to GST–NC,
as quantified by phosphorimager analysis (data not
shown). Background level of binding could be detected
on GST. As a control for the specificity of Vif/NC interac-
tion through the Zn finger motifs, we measured the bind-
ing between Vif and an irrelevant Zn finger containing
protein. The chosen protein was teashirt, a DNA binding
protein with three Zn finger motifs, involved in the devel-
opment of Drosophila (Alexandre et al., 1996; Fasano et
l., 1991). No binding was observed between Vif and the
ST–teashirt fusion protein (data not shown). These re-
ults demonstrated that the interaction of CAEV Vif with
he viral NC domain of the Pr55gag was specific and was
e amplified by RT–PCR on RNA extracted from virions pelleted by
, between positions 26 and 216, were deduced from the nucleotidic
introduced between positions 27 and 31, 54 and 83, 140 and 190 and
to the wt sequence. In the Vif wt sequence, the amino acid residues
e original Vif RG mutant only the W95R and S197G substitutions weres wer
uences
s were
mparedependent on the presence of the two NC Zn finger
otifs.
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236 SEROUDE ET AL.Analysis of Vif mutants interaction with GST–Pr55gag
or GST–NC
Having demonstrated that interaction of CAEV Vif
with the Pr55gag occurred at the NC domain, we then
tested whether this interaction could represent one of
the molecular mechanisms involved in the Vif function
on viral replication. The five-point mutant Vif proteins
were in vitro translated in the presence of [35S]methi-
onine and allowed to react with equal amounts of GST,
GST–NC, or GST–Gag proteins. Attempts to translate
deletion mutants of the CAEV Vif protein were unsuc-
cessful since these mutants proved to be either un-
stable or very inefficiently synthetised in the in vitro
translation system (G. Audoly, unpublished results). As
shown in Fig. 5, the Vif S197G, Vif RG, Vif S170E, or Vif
S170G proteins bound to GST–NC or GST–Gag to the
FIG. 4. In vitro interaction between CAEV Vif and Gag proteins. The d
part of the figure. Pictures of representative interaction experiments
recombinant GST–Vif protein in the presence of increasing NaCl con
GST–CA, or GST–NC at various NaCl concentrations. (C) Interaction of
Zn finger motif (GST–NC Z1* and GST–NC Z2*, respectively). Equal am
incubated with in vitro translated 35S-labelled proteins. The amount of ra
roteins were eluted, resolved on 12% SDS–PAGE and revealed by ausame extent as the wt protein. All but the Vif RG were
associated to a wt replication phenotype (Fig. 2B). On
s
tthe contrary, the Vif 6mut protein demonstrated a 10-
fold less interaction capacity compared to the Vif wt,
as determined by phosphorimager analysis (data not
shown), while being impaired for replication (Fig. 2A).
No interaction could be detected between all these
proteins and GST. These results suggested that serine
residues at positions 170 and 197 were neither impli-
cated in virus replication nor in Vif/Gag interaction.
The five amino acid sequence at position 120–124
defined a Vif region either directly involved in interac-
tion and replication, or important to maintain the native
protein conformation. These results suggested that
the interaction, in an in vitro GST fusion-based assay,
etween CAEV Vif and the NC domain of the Pr55gag,
ight be through conformational domains of both pro-
eins. Interestingly, the Trp95 amino acid residue, es-
t proteins tested in the GST binding assay are schematized on the left
own on the right part of the figure. (A) Binding of 35S-Pr55gag to the
ions. (B) Binding of 35S-Vif to the fusion proteins GST–Gag, GST–MA,
ith GST–NC or with the mutant proteins modified in the first or second
of GST or GST–fusion proteins were bound to glutathione beads and
ve material used for each assay is shown in the left lane (input). Bound
graphy.ifferen
are sh
centrat
35S-Vif w
ountsential for virus replication, seems to be unrelated to
he Gag binding domain.
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237FUNCTIONAL DOMAIN OF CAEV VIF PROTEINDISCUSSION
In this study, we analyzed the replication phenotype as
ell as the Gag interaction of several CAEV Vif point
utants in order to define functional motifs or domains.
he results are summarized in Table 1. The Vif mutants
arboring mutations on Ser 170 or Ser197 (Vif S170E,
170G or S197G) were indistinguishable from Vif wt con-
erning their interaction with Gag and their replication
FIG. 5. In vitro interactions of CAEV Vif mutants with GST–Gag or GS
equal amounts of GST, GST–NC, or GST–Gag fixed to glutathione bea
to Fig. 4.
TABLE 1
Results Summary
Vif sequence
Interaction with the NC
domain of the Pr55gaga
Replication in
CFSM cellsb
wt 1 1
S170E 1 1
S170G 1 1
6mut 2 2
S197G 1 1
RG 1 2
RG-1 1 2
RG-2 1 1
Note. Summary of the results obtained with the different CAEV Vif
mutants as to their interaction with the NC domain of the Pr55gag (a) and
heir replication phenotype in target cells (b).
a 1 indicates the detection of Vif/Gag interaction in the GST binding
ssay; 2 strongly diminished or lack of interaction.b 1 indicates a CAEV Vif wt replication phenotype; 2 is for a strongly
ttenuated replication (Vif2 phenotype).henotype. These serine residues were targeted for mu-
agenesis for several reasons, (i) both are in the C-
erminal region of Vif, and Ser170 is contained within the
ighly conserved SLQXLA motif in Vif proteins from all
entiviruses. Our previous work had shown that deletion
f this motif resulted in CAEV impaired replication (Har-
ache et al., 1995), whereas studies on HIV-1 and SIV-
ac revealed the importance of Ser144 phosphorylation
n this motif for Vif function (Simon et al., 1999b; Yang et
l., 1996). (ii) Both are thought to be potentially phosphor-
lated since they are localized in the context of recogni-
ion motifs used by serine/threonine protein kinases,
AMP- and cGMP-dependent protein kinase for Ser170
nd Ser197, but also casein kinase II for Ser197. The
resent results showed that substitution of serine by
ither glycin or glutamic acid residues did not modify
AEV Vif activity, suggesting that phosphorylation of
er170 or Ser197, if any, has no effect on CAEV Vif
unction. Computer data-base searches identified other
otentially phosphorylated sites in the CAEV Vif se-
uence. Whether phosphorylation of these different res-
dues plays a role in regulation of CAEV Vif function
eeds further analysis. Among the Vif mutants tested in
his study, only the Vif 6mut protein exhibited both a Vif2
phenotype when replaced into the CAEV molecular clone
while being largely impaired in its interaction with Gag.
In this mutant, the original DRHFW (120–124) amino acid
he different 35S-labelled Vif wt or mutant proteins were incubated with
e presence of 0.15 M MaCl and analyzed as described in the legendT–NC. Tsequence was replaced by SIVSR. The Phe-Trp residues
are highly conserved among all known visna/CAEV Vif
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238 SEROUDE ET AL.sequences, and as non-polar amino acid residues, they
are thought to be inside the protein. Their replacement
by two polar amino acid residues, Ser-Arg, which are
rather exposed on the outside of the protein, might have
imposed a conformational change of the secondary
structure of the CAEV Vif protein, thus having a strong
impact on the replication phenotype and resulting in a
10-fold less interaction capacity with Gag than the Vif wt.
This result strengthens the current idea that structure-
function studies on the lentiviral Vif proteins are hindered
by their unusual biochemical properties (Gabuzda et al.,
1992; Harmache et al., 1995; Oberste and Gonda, 1992;
Simon et al., 1999b; Yang et al., 1996).
Interestingly, the Vif RG mutant allowed us to demon-
strate that the in vitro Vif/Gag interaction per se did not
orrelate with the Vif function on the viral replication
ycle. Indeed the Vif RG protein bound to the GST–Gag or
ST–NC as efficiently as the Vif wt, while showing a Vif2
phenotype when introduced into the CAEV molecular
clone. The Vif RG mutant protein contains the S197G and
W95R substitutions. As the S197G modification was dem-
onstrated to have no influence on Vif activity, it can be
argued that the phenotype of the Vif RG mutant was due
to the W95R substitution. Tryptophan at position 95 is
localized in a strictly conserved WQYK sequence of Vif
visna/CAEV isolates and its replacement by the polar
arginine amino acid residue might result in the disruption
of a functional domain of the protein. However, this
change had only consequence on viral infectivity, sug-
gesting that the two Vif properties examined in this study
are independent and might be mediated by different
functional domains of the protein. The critical role of
Trp95 for Vif function in viral infectivity was assessed by
the isolation of viruses that reverted from the Arg95
mutant to the wt sequence during the time course of
infection. This result confirms our previous studies on a
CAEV Vif NcoI2 mutant (Harmache et al., 1995), in which
frameshift insertion of 4 bp at the NcoI site resulted in
truncated 140 amino acids protein, showing an unre-
ated sequence starting at Trp95. Analysis of the vif gene
equences, contained within virions released during in-
ection, revealed that reversions occurred in the variable
3–94 amino acid region, that resulted in restoration of
ull-length wt Vif sequence, starting at Trp95. These re-
ults suggest that this position is submitted to a high
election pressure and might represent an important
unctional region. In the case of HIV-1, the amino-terminal
rp21 residue was recently shown to be functionally
mportant for Vif function in non-permissive cells (Boyce
t al., 1999). Altogether, these results led us to think that
he many tryptophan residues conserved among visna/
AEV or HIV/SIV isolates might be essential in interac-
ions with host cellular factor(s) important for the viral
henotype.We demonstrated in vitro CAEV Vif/Gag interactions
sing the GST-binding assay, at the NC domain of ther55gag. This interaction seems to occur through recog-
nition of the native conformation of the NC domain since
mutations resulting in the misfolding of the first or sec-
ond Zn finger motif largely diminished the interaction
with Vif. Since such retroviral NC mutants are generally
known to be impaired in their binding to nucleic acid
molecules, it remains to be determined whether the Vif
fixation to NC is the result of direct interaction between
these proteins or is mediated via the nucleic acid-NC
complex. Recent reports described the HIV-1 Vif protein
as an RNA binding protein (Dettenhofer et al., 2000;
Zhang et al., 2000). In the case of CAEV, we performed
RNase treatments of each GST–NC and Vif protein be-
fore or after interaction, but we could not observe any
modification in the binding capacity of the treated. How-
ever, we could not exclude that short RNA sequences
bound to the GST–NC and/or Vif proteins could be pro-
tected from the RNase action due to this binding (data
not shown). Since it seems that in vitro Vif/Gag interac-
tion is not directly related to Vif activity, the biological
significance of these interactions is still an open ques-
tion. Lentiviral Vif proteins are commonly recognized to
be multi-functional proteins. In the case of HIV-1 Vif, the
N-terminal domain is associated to the inhibition of viral
protease activity (Kotler et al., 1997; Potash et al., 1998),
while the C-terminal part is required for Gag and cell
membrane binding (Bouyac et al., 1997a; Goncalves et
al., 1994; Simon et al., 1997). Co-localization, interaction,
nd membrane association of HIV-1 Vif and Gag are
ubject to controversial results (Simon et al., 1999a) as
well as the importance of the Vif C-terminal domain for
interaction and function. Indeed, whereas some studies
reported a 30% loss of Vif/Gag interaction using an HIV-1
Vif protein deleted of its 22 C-terminal amino acid resi-
dues (Bouyac et al., 1997a) or the characterization of
amino acid residues or domain in this region essential
for Vif activity (Bouyac et al., 1997b; Goncalves et al.,
1994, 1995; Simon et al., 1999b), another report described
the unimpaired function of a natural C-terminal truncated
Vif protein derived from a primary HIV-1 isolate (Ochsen-
bauer et al., 1996). In the caprine lentivirus, deletion of
amino acids 189–205 from the Vif sequence was asso-
ciated with an attenuated replication phenotype (Harma-
che et al., 1995), whereas deletion of the last 24 C-
terminal amino acid residues had no effect on the ca-
pacity to interact with the Pr55gag (G. Audoly, unpublished
esults).
In vitro Vif/Gag specific interactions, now described for
IV-1 and CAEV, would not necessarily mean a stable
ssociation between these two proteins. It could be
ypothesized that Vif interacts transiently with the Pr55gag
and also with species specific cellular factor(s) (Simon et
al., 1995, 1998b) at the site of virus assembly to allow the
efficient production of infectious viruses. On the other
hand and during earlier steps of the replication cycle, Vif
might counteract an inhibitory activity associated to non-
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al., 1998b) as well as regulate the viral protease activity.
Definitive confirmation of the different functions and of
the multiple viral or cellular partners of Vif still requires
further studies to allow a better understanding of the
regulation of lentiviruses replication.
MATERIALS AND METHODS
Construction of pGEX plasmids
The open reading frames of CAEV gag and vif were
amplified by PCR from the PK-9kb plasmid (Turelli et al.,
1996) derived from the CAEV Cork infectious molecular
clone (Saltarelli et al., 1990). The PCR product of gag (nt
512–1859), obtained using the GagGEXI/CRT27 primer
pair, was cloned into the BamHI site, in frame with the
glutathione S–transferase gene into the pGEX-5X-2 vec-
tor (Pharmacia). The MA (nt 512–940) and NC (nt 1616–
1859) coding sequences were cloned into the BamHI/
EcoRI sites of the pGEX-5X-2 vector to produce the
pGEX-MA and pGEX-NC plasmids, respectively. These
plasmids were kindly provided by Dr. P. Turelli. The Z1
and Z2 NC mutants obtained by PCR with the SZ1/RZ1
and SZ2/RZ2 primer pairs, respectively, were inserted in
frame into the EcoRI site of the pGEX-5X-2 vector. The
GST-CA contained the entire coding sequence of the
maedi-visna virus CA domain and the 39-94 bp and 59-96
bp flanking sequences from MA and NC, respectively.
This construct was kindly provided by Dr. Zanoni, Insti-
tute of Veterinary Virology, Bern, Switzerland (Zanoni et
al., 1992). Amplification products of the CAEV vif gene (nt
5006–5692), using the VCECO/VCASECO primer pair,
were cloned at the EcoRI site of the pGEX-5X-2 vector to
obtain the pGEX-vif plasmid.
Mutagenesis of the CAEV vif gene
The vif gene of CAEV was amplified by PCR reaction
using the high-fidelity thermostable polymerase (Roche)
and the T3VC/VCASECO primer pair. The forward primer
contains the T3 RNA polymerase recognition site up-
stream from the ATG initiation codon. The PCR product
was directly cloned into the pTA cloning vector (Invitro-
gen) to generate the pTA-vif plasmid. Site-directed mu-
tagenesis of the CAEV vif gene was realized by PCR on
the pTA-vif plasmid. Different Vif mutants were created:
Vif S170G was mutated at position 170 where serine was
substituted by glycine (using the S170G/RS170G prim-
ers); Vif S170E where serine was substituted by glutamic
acid (using the S170E/RS170E primers); and Vif S197G
where the serine was substituted by a glycine (using the
S197G/RS197G primers). Vif mutants that present both
S197G and W95R mutations or both S170G and the sub-
stitution mutations at positions 120–124 (DRHFW/SIVSR)
were randomly obtained, and characterized by DNA se-
quencing (Genome Express, Grenoble, France).
aCAEV Vif mutants molecular clones were obtained as
follows: the BstEII-DraIII fragment (positions 3879–6640)
was excised from the PK-9kb plasmid and subcloned
into pUC19, to generate the pUC19-vif plasmid. The
BamHI and MluI restriction sites were then created by
PCR at positions 5079 and 5636, using the SBHI/RBHI
and the 33MluI/ASMluI primer pairs, respectively. The
different vif mutant genes were amplified from the re-
spective pTA-vif plasmids using the SBHI/ASMluI prim-
ers. After BamHI-MluI digestion, the vif genes were
cloned at these restriction sites into the pUC19-vif plas-
mid. The BstEII-DraIII fragment was then cloned at these
sites into the PK-9kb plasmid.
Nucleotidic sequence determination
Sequences of the vif genes, contained within progeny
virions produced by cells infected with the different
CAEV Vif mutants, were determined from RT–PCR prod-
ucts of the extracted RNA. Virions were concentrated
from cell-free supernatants by ultra-centrifugation at
100 000 g for 45 min at 4°C. The viral pellets were
resuspended in 300 ml RNAB (Bioprobe) and processed
for RNA extraction according to the manufacturer’s rec-
ommendations. One microliter of RNA was submitted to
RT–PCR to amplify the vif gene, using the VCP/R10
primer pair and the SuperScript One Step RT–PCR kit
(Life Technologies). Amplification products were purified
from a 1% agarose gel, digested with BamHI/MluI and
cloned into the pGEM-T Easy vector (Promega). The
pGEM-vif plasmids were then transformed into Esche-
richia coli DH5a, and recombinant colonies were se-
lected. DNA extracted from different clones were then
sequenced using the VC5079/ASMluI primer pair (Ge-
nome Express, Grenoble, France) allowing the Vif amino
acid sequence deduction from positions 26 to 216.
In vitro protein translation
The Gag and Vif proteins synthesis was performed
with the TnT T3 wheat germ extract systems (Promega)
following the manufacturer’s recommendations. The gag
gene was amplified from the PK-9kb plasmid with the
T3GC/R27II primer pair. The vif genes were amplified
from the different pTA-vif plasmids using the T3VC/
VCASECO primer pair. The PCR products were used to
allow proteins transcription/translation in the presence
of [35S]methionine (.1000 Ci/mmol; Amersham). The ra-
iolabelled products were resolved on 12% polyacryl-
mide gel electrophoresis (SDS–PAGE) and revealed by
utoradiography using Kodak X-OMat films.
ligonucleotides
The oligonucleotides used were as follows (the restric-
ion sites are underlined and the substituted nucleotides
re in bold): GagGEX1 59-CGGGATCCTGGTGAGTCTAG-39
(nt 514–524); CRT27 59-CGGGATCCATAGGTGGTGGTA-
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240 SEROUDE ET AL.AG-39 (nt 1876–1859); SZ1 (59-GCCACAAAGGGGTTA-
CAACGGTGGAAAACCGGGACATCAAGC-39 (nt 1663–1704);
Z1 59-CCACCGTTGTAACCCCTTTGTGGCTGTCCATTCC-39
nt 1686–1653); SZ2 59-GGAATCATAGGTCTCAACGGTG-
AAAGAGAGGACATATGC-39 (nt 1721–1760); RZ2 59-CCAC-
GTTGAGACCTATGATTCCTTGACTACATTGCC-39 (nt 1743–
707); VCECO 59-CGGAATTCAAAATTCATCCCGCCAC-39
(nt 5009-5026); VCASECO 59-CGGAATTCTCACTCATC-
CTCTAA (5695–5681); T3VC 59-CGAATTACCCTCACTAAA-
GAAAGAAGGATGCAAAATTCATCCCGC-39 (nt 5006–5023);
S170G 59-GAACAAAAGGTCTGGAAAGACTAGTACTG-39 (nt
505–5533); RS170G 59-TCTTTCCAGACCTTTTGTTCTAG-
ATGC-39 (nt 5524–5497); S170E 59-AGAACAAAAGAGCTG-
AAAGACTAGTACTGCTAC-39 (nt 5504–5537); RS170E 59-
AGTCTTTCCAGCTCTTTTGTTCTAGTATGCTTTAC-39 (nt
527–5492); S197G 59-GGAGAAGTGGTACAACAGATTTC-
CATGG-39 (nt 5586–5614); RS197G 59-ATCTGTTGTACCA-
TTCTCCTGGCTCTCC-39 (nt 5605–5577); SBHI59-GCA-
TATGGATCCATATAGCAGAAAGCATTAAT (nt 5072–5104);
RBHI 59-TTCTGCTATATGGATCCATAGTGCTAAGGGTAA-39 (nt
5095–5065); 33MluI 59-GGATACACGCACGCGTGGTCTGTC-
CAGGAGTGC-39 (nt 5630–5662); ASMluI 59-GACAGACC-
CGCGTGCGTGTATCCCGTTG-39 (nt 5653–5625); T3GC
59-CGAATTACCCTCACTAAAGAAAGAAGGCCGCCATGGT-
GAGTCTAGATAGAG-39 (nt 512–530); R27II 59-GCCAGATC-
TCCATAGGTGGTGCTGAAG-39 (nt 1876–1859); VCP 59-
CGGGATTCCCCAAAATTCATCCCGCCACC-39 (nt 5009–
5027); R10 59-CCCAGTTAAGCGCATGTATC-39 (nt 5927–5908);
VC5079 59-GGATCCATATAGCAGAAAGC (nt 5079–5098).
Expression and purification of GST fusion proteins
E. coli top 10 colonies transformed with pGEX recom-
binant plasmids were grown in LB medium containing
100 mg/ml ampicillin at 37°C until an OD600 nm of ;1.
Expression of the fusion proteins was then induced with
1 mM IPTG for 3 h at 30°C. Bacterial cultures were then
pelleted by centrifugation at 5000 g for 15 min at 4°C and
resuspended in 1/10 vol of MT-PBS (150 mM NaCl, 12.5
mM Na2HPO4, 2.5 mM KH2PO4, and 100 mM EDTA, pH
.5). The bacteria were lysed on ice by mild sonication,
nd the lysate, brought to 1% Triton X-100, was incubated
n ice for 30 min before clearing by centrifugation at
5,000 g for 30 min at 4°C. Glutathione–agarose beads
Sigma), previously resuspended in MT–PBS, were
dded to the cleared supernatant for 1 h at 4°C. Beads
ere then extensively washed in 1 M NaCl, then in
BS-0.1% Triton-X-100 supplemented with protease in-
ibitor cocktail (aprotinin, leupeptin, pepstatin A, and
ntipain at 1 mg/ml, PMSF 100 mg/ml, pefabloc 200
mg/ml). Beads were then resuspended in SDS–PAGE
sample buffer, and the eluted GST fusion proteins were
resolved on 12% SDS–PAGE. Proteins were visualised by
Coomassie blue staining and quantified using a Bradford
assay (Micro BCA, Pierce).In vitro binding assays
Equal amounts (2–5 mg) of GST or GST fusion proteins
ound to glutathione–agarose beads were incubated
ith 35S-methionine-labelled Gag or Vif proteins in TNT
inding buffer containing 50 mM Tris–HCl pH 7.6, 0.2%
ween 20, 100 mg/ml bovine serum albumin, and differ-
ent concentrations of NaCl (0.1–1 M) for 1 h at 4°C.
Beads were then washed in TNT buffer and resuspended
in SDS–PAGE sample buffer. The eluted proteins were
resolved on 12% SDS–PAGE, revealed by autoradiogra-
phy and quantified with a Fuji phosphorimager. The data
were analyzed by MacBas V2.5 software (Fuji Photo Film
Co, Ltd).
Cells, transfection, and infection
Primary goat synovial membrane cells (CFSM) were
derived from the carpal joint of an healthy animal and
maintained in culture in Eagle’s minimal essential me-
dium (MEM) supplemented with 2 mM glutamin, 100
IU/ml penicillin, 100 mg/ml streptomycin, and 10% fetal
calf serum (Life Technologies). Transfections of 50 3 104
CFSM cells were performed, using the Lipofectamine
reagent (Life Technologies), with 5 mg of a mixture of
K-9kb and BS-39LTR (Turelli et al., 1996) to allow recon-
titution of proviral DNA. The medium was changed
very 3–4 days, and the supernatants were harvested for
everse transcriptase (RT) activity measurement. Infec-
ions were carried out with CAEV wild-type (wt) or CAEV
if mutant supernatants containing the same RT activity
10,000 cpm per 25 cm2 flask), for 2 h at 37°C on sub-
confluent CFSM cells. Infection was monitored by RT
activity measurement in the cell free supernatant. Mea-
surement of RT activity was performed as previously
described (Harmache et al., 1995).
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